NewsBite analysis · AI, Cloud, HealthTech, Startups
Financial Times
Anthropic launches Claude Science in push for pharma revenue
Anthropic has unveiled Claude Science, its first dedicated AI product for scientists and pharmaceutical companies. The tool is designed to aid in drug discovery by offering capabilities such as 3D protein structure rendering. This launch is part of Anthropic's strategy to expand its enterprise offerings and establish new revenue streams, particularly as it anticipates going public soon. With increased interest from big pharma, the product aims to minimize the gap in scientific research execution and enhance capabilities in the life sciences.
Act nowConfidence: HighImmediate horizon
Published 30 Jun 2026, 18:40 UTC3 min read
Visit original article ↗Lead image — Financial Times
Summary
TL;DR
- Claude Science targets the pharmaceutical and scientific communities.
- Aims to enhance efficiencies in drug discovery and research.
- Comes amid pressure for Anthropic to stabilize growth and address concerns.
- Anthropic is expected to go public, valuing it potentially over $1 trillion.
- Existing partnerships with pharmaceutical companies highlight demand.
Interesting facts
- Claude Science represents Anthropic's venture into the life sciences market.
- The product runs on current Claude models, expanding the company’s capabilities.
- Significant partnerships with big pharma emphasize AI's growing role in drug discovery.